543064 Stock Overview
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 543064 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cohance Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,078.40 |
| 52 Week High | ₹1,359.00 |
| 52 Week Low | ₹597.00 |
| Beta | 1.13 |
| 1 Month Change | -6.19% |
| 3 Month Change | -3.74% |
| 1 Year Change | 66.18% |
| 3 Year Change | 106.35% |
| 5 Year Change | 580.16% |
| Change since IPO | 541.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 543064 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.3% | 0.2% | 2.3% |
| 1Y | 66.2% | 13.0% | 3.9% |
Return vs Industry: 543064 exceeded the Indian Pharmaceuticals industry which returned 13% over the past year.
Return vs Market: 543064 exceeded the Indian Market which returned 3.9% over the past year.
Price Volatility
| 543064 volatility | |
|---|---|
| 543064 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: 543064 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 543064's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Sudhir Singh | www.cohance.com |
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals.
Cohance Lifesciences Limited Fundamentals Summary
| 543064 fundamental statistics | |
|---|---|
| Market cap | ₹275.39b |
| Earnings (TTM) | ₹2.79b |
| Revenue (TTM) | ₹10.48b |
98.4x
P/E Ratio26.2x
P/S RatioIs 543064 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 543064 income statement (TTM) | |
|---|---|
| Revenue | ₹10.48b |
| Cost of Revenue | ₹3.90b |
| Gross Profit | ₹6.58b |
| Other Expenses | ₹3.79b |
| Earnings | ₹2.79b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 28, 2025
| Earnings per share (EPS) | 10.97 |
| Gross Margin | 62.78% |
| Net Profit Margin | 26.63% |
| Debt/Equity Ratio | 1.9% |
How did 543064 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 11:52 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cohance Lifesciences Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijayaraghavan Swaminathan | Avendus Spark |
| Harith Ahamed | Avendus Spark |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |